Infliximab, adalimumab, certolizumab pegol ( DrugBank: Adalimumab, Infliximab, Certolizumab pegol )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	1
97	潰瘍性大腸炎	1

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02073526 (ClinicalTrials.gov)	May 2013	9/1/2014	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Infliximab, adalimumab, certolizumab pegol	Oslo University Hospital	NULL	Completed	18 Years	N/A	Both	1230	N/A	Norway

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02073526 (ClinicalTrials.gov)	May 2013	9/1/2014	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Infliximab, adalimumab, certolizumab pegol	Oslo University Hospital	NULL	Completed	18 Years	N/A	Both	1230	N/A	Norway